Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
NewAmsterdam Pharma Company N.V. (NAMS) had Return on Equity of -29.82% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$22.50M |
|
$-203.82M |
|
-- |
|
$22.50M |
|
$248.19M |
|
$-225.68M |
|
$21.86M |
|
$-203.82M |
|
$-203.82M |
|
$-203.82M |
|
$-203.82M |
|
$-203.82M |
|
$-203.82M |
|
$-225.68M |
|
$-225.46M |
|
118.42M |
|
118.42M |
|
$-1.72 |
|
$-1.72 |
|
| Balance Sheet Financials | |
$675.70M |
|
$0.38M |
|
$93.58M |
|
$769.28M |
|
$85.79M |
|
-- |
|
$0.07M |
|
$85.85M |
|
$683.43M |
|
$683.02M |
|
$683.43M |
|
114.40M |
|
| Cash Flow Statement Financials | |
$-147.78M |
|
$-174.92M |
|
$29.52M |
|
$771.74M |
|
$491.32M |
|
$-280.42M |
|
$59.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1002.90% |
|
-1002.90% |
|
-1001.92% |
|
-905.74% |
|
-905.74% |
|
$-148.03M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-29.82% |
-29.84% |
|
-26.49% |
|
-29.82% |
|
$5.97 |
|
$-1.25 |
|
$-1.25 |
|